3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Small Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
5
tislelizumab
2
spartalizumab
2
Trastuzumab
2
Psychiatric Rehabilitation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-12 Subunit p35
2
Erlotinib Hydrochloride
2
Biopsy
2
trastuzumab deruxtecan
1
tipifarnib
1
regorafenib
1
prexasertib
1
niraparib
1
fludarabine
1
enzalutamide
1
entinostat
1
abiraterone
1
Vorinostat
1
Thalidomide
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Radionuclide Imaging
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
abiraterone
×
Thoracic
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts